{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Neuroendocrine+Tumor&page=2",
    "query": {
      "condition": "Lung Neuroendocrine Tumor",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Neuroendocrine+Tumor&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T19:02:15.797Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02308020",
      "title": "A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Non-small Cell Lung Cancer",
        "Melanoma",
        "Brain Metastases"
      ],
      "interventions": [
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 162,
      "start_date": "2015-04-20",
      "completion_date": "2019-11-08",
      "has_results": true,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-06-25T19:02:15.797Z",
      "location_count": 19,
      "location_summary": "Duarte, California • La Jolla, California • San Francisco, California + 15 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02308020"
    },
    {
      "nct_id": "NCT04276597",
      "title": "Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Neuroendocrine Neoplasm",
        "Pheochromocytoma",
        "Paraganglioma",
        "Thymus Carcinoid",
        "Unknown Primary Tumors",
        "Neuroendocrine Tumors",
        "Neuroendocrine Skin Carcinoma",
        "Neuroendocrine Breast Tumor",
        "Neuroendocrine Carcinoma Metastatic",
        "Neuroendocrine Neoplasm of Ovary"
      ],
      "interventions": [
        {
          "name": "177Lu-DOTATOC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Excel Diagnostics and Nuclear Oncology Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-03-04",
      "completion_date": "2021-07-15",
      "has_results": false,
      "last_update_posted_date": "2023-03-10",
      "last_synced_at": "2026-06-25T19:02:15.797Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04276597"
    },
    {
      "nct_id": "NCT06270082",
      "title": "Study of IK-595 in RAS- or RAF-altered Advanced Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Colorectal Cancer",
        "Pancreatic Cancer",
        "Malignant Melanoma",
        "Ras (Kras or Nras) Gene Mutation",
        "BRAF Gene Mutation",
        "CRAF Gene Mutation",
        "Non-Small Cell Lung Carcinoma",
        "Thyroid Carcinoma",
        "Gliomas, Malignant"
      ],
      "interventions": [
        {
          "name": "IK-595",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ikena Oncology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2023-12-18",
      "completion_date": "2025-09-08",
      "has_results": false,
      "last_update_posted_date": "2025-09-19",
      "last_synced_at": "2026-06-25T19:02:15.797Z",
      "location_count": 15,
      "location_summary": "Duarte, California • Orange, California • Denver, Colorado + 12 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06270082"
    },
    {
      "nct_id": "NCT02475213",
      "title": "Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Head and Neck Cancer",
        "Non Small Cell Lung Cancer",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Enoblituzumab Schedule 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Enoblituzumab Schedule 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "retifanlimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 146,
      "start_date": "2015-07",
      "completion_date": "2021-08-18",
      "has_results": true,
      "last_update_posted_date": "2025-08-11",
      "last_synced_at": "2026-06-25T19:02:15.797Z",
      "location_count": 20,
      "location_summary": "Scottsdale, Arizona • Newark, Delaware • Jacksonville, Florida + 17 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02475213"
    },
    {
      "nct_id": "NCT00937482",
      "title": "Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Male Breast Cancer",
        "Stage IV Breast Cancer",
        "Stage IV Melanoma",
        "Stage IV Non-small Cell Lung Cancer",
        "Stage IV Renal Cell Cancer",
        "Stage IVA Colon Cancer",
        "Stage IVA Rectal Cancer",
        "Stage IVB Colon Cancer",
        "Stage IVB Rectal Cancer",
        "Tumors Metastatic to Brain"
      ],
      "interventions": [
        {
          "name": "cediranib maleate",
          "type": "DRUG"
        },
        {
          "name": "whole-brain radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2009-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-03-08",
      "last_synced_at": "2026-06-25T19:02:15.797Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00937482"
    },
    {
      "nct_id": "NCT04604158",
      "title": "Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer",
        "Cancer Metastatic",
        "Neoplasms",
        "Breast Cancer",
        "Lung Cancer",
        "Glioblastoma",
        "Prostate Cancer",
        "Gynecologic Cancer",
        "Colorectal Cancer",
        "Sarcoma",
        "Kidney Cancer",
        "Bladder Cancer",
        "Lymphoma",
        "Leukemia",
        "Head and Neck Cancer",
        "Pancreas Cancer",
        "Multiple Myeloma",
        "Anxiety",
        "Social Isolation",
        "Stress",
        "Loneliness",
        "Melanoma",
        "Uterine Cancer"
      ],
      "interventions": [
        {
          "name": "Elly Mobile Phone Application",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Gillian Gresham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2020-12-02",
      "completion_date": "2024-05-17",
      "has_results": false,
      "last_update_posted_date": "2024-05-21",
      "last_synced_at": "2026-06-25T19:02:15.797Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04604158"
    },
    {
      "nct_id": "NCT01390818",
      "title": "Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced Solid Tumor",
        "Metastatic Solid Tumor",
        "Breast Cancer",
        "Non Small Cell Lung Cancer",
        "Melanoma",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "MSC1936369B (pimasertib)",
          "type": "DRUG"
        },
        {
          "name": "SAR245409 (PI3K and mTOR inhibitor)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "82 Years",
        "sex": "ALL",
        "summary": "18 Years to 82 Years"
      },
      "enrollment_count": 146,
      "start_date": "2011-05",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2017-03-07",
      "last_synced_at": "2026-06-25T19:02:15.797Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01390818"
    },
    {
      "nct_id": "NCT00178698",
      "title": "Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroendocrine Cancer",
        "Small Cell Lung Cancer",
        "Non-Small Cell Lung Cancer",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "thermochemotherapy",
          "type": "OTHER"
        },
        {
          "name": "Cisplatin, Gemcitabine, Interferon-a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2002-07",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2011-03-03",
      "last_synced_at": "2026-06-25T19:02:15.797Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00178698"
    },
    {
      "nct_id": "NCT03767348",
      "title": "Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer (NSCLC)",
        "Microsatellite Instability-High (MSI-H)",
        "Non-melanoma Skin Cancer (NMSC)",
        "Cutaneous Melanoma"
      ],
      "interventions": [
        {
          "name": "RP1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Replimune, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 340,
      "start_date": "2017-09-20",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-06-25T19:02:15.797Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03767348"
    },
    {
      "nct_id": "NCT07174583",
      "title": "A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Small-cell Lung Cancer",
        "Neuroendocrine Carcinomas",
        "Solid Tumor Show to Express DLL3"
      ],
      "interventions": [
        {
          "name": "IDE849",
          "type": "DRUG"
        },
        {
          "name": "durvalumab",
          "type": "DRUG"
        },
        {
          "name": "IDE161",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IDEAYA Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 208,
      "start_date": "2025-10-14",
      "completion_date": "2029-05",
      "has_results": false,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-06-25T19:02:15.797Z",
      "location_count": 20,
      "location_summary": "Denver, Colorado • Jacksonville, Florida • Orlando, Florida + 14 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07174583"
    }
  ]
}